UPDATE: Egalet, On Market Potential Of Its ARMYO ER In Light Of FDA Vote On Endo's Opana ER, Highlights to Benzinga ARYMO ER Has IV-Abuse Deterrent Claim, Gelling Properties Resist Passage Through Syringe
Hal Lindon